Bartlomiej Milanowski
Overview
Explore the profile of Bartlomiej Milanowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Czajkowski M, Slaba A, Milanowski B, Bauer-Brandl A, Brandl M, Skupin-Mrugalska P
Eur J Pharm Sci
. 2024 Oct;
203:106936.
PMID: 39414171
In the current study, it was demonstrated that three commercially available grades of hydrogenated phospholipids (HPL) differing in their content of phosphatidylcholine may be used as components for hot melt-extruded...
2.
Wosicka-Frackowiak H, Poniedzialek K, Wozny S, Kuprianowicz M, Nyga M, Jadach B, et al.
Polymers (Basel)
. 2024 Sep;
16(18).
PMID: 39339133
Biomaterials have been the subject of extensive research, and their applications in medicine and pharmacy are expanding rapidly. Collagen and its derivatives stand out as valuable biomaterials due to their...
3.
Baran E, Birczynski A, Milanowski B, Klaja J, Nowak P, Dorozynski P, et al.
ACS Appl Mater Interfaces
. 2024 Jul;
16(31):40714-40725.
PMID: 39056539
The hypothesis of the study was that (1) 3D printed drug delivery systems (DDS) could be characterized in situ during drug release using NMR/MRI techniques in terms of mass transport...
4.
Kulinowski P, Malczewski P, Laszcz M, Baran E, Milanowski B, Kuprianowicz M, et al.
Materials (Basel)
. 2022 Mar;
15(6).
PMID: 35329594
3D printing by selective laser sintering (SLS) of high-dose drug delivery systems using pure brittle crystalline active pharmaceutical ingredients (API) is possible but impractical. Currently used pharmaceutical grade excipients, including...
5.
Minecka A, Chmiel K, Jurkiewicz K, Hachula B, Lunio R, Zakowiecki D, et al.
Mol Pharm
. 2021 Dec;
19(1):80-90.
PMID: 34851124
In this paper, several experimental techniques [X-ray diffraction, differential scanning calorimetry (DSC), thermogravimetry, Fourier transform infrared spectroscopy, and broad-band dielectric spectroscopy] have been applied to characterize the structural and thermal...
6.
Jakubowska E, Milanowski B, Lulek J
Int J Mol Sci
. 2021 Nov;
22(22).
PMID: 34830298
Nanosizing is an approach to improve the dissolution rate of poorly soluble drugs. The first aim of this work was to develop nanosuspension of cilostazol with liquid antisolvent precipitation (LASP)...
7.
Wroblewska K, Milanowski B, Kucinska M, Plewa S, Dlugaszewska J, Muszalska-Kolos I
Pharmaceuticals (Basel)
. 2021 Sep;
14(9).
PMID: 34577550
This work investigated the potential of a novel formulation of eye drops containing a non-steroidal anti-inflammatory drug-choline salicylate (CS)-and hyaluronic acid (HA). Thus, these drops may exert both anti-inflammatory and...
8.
Milanowski B, Wosicka-Frackowiak H, Glowka E, Sosnowska M, Wozny S, Stachowiak F, et al.
Pharmaceutics
. 2021 Aug;
13(8).
PMID: 34452264
Pharmaceutical products containing non-steroidal anti-inflammatory drugs (NSAIDs) are among the most prescribed topical formulations used for analgesic and antirheumatic properties. These drugs must overcome the skin barrier to cause a...
9.
Skotnicki M, Jadach B, Skotnicka A, Milanowski B, Tajber L, Pyda M, et al.
Pharmaceutics
. 2021 Jan;
13(1).
PMID: 33477672
The aim of this study was to characterize a 1:1 molar ratio of a pharmacologically relevant co-amorphous atorvastatin-irbesartan (ATR-IRB) system obtained by quench cooling of the crystalline ATR/IRB physical mixture...
10.
Danielak D, Milanowski B, Wentowski K, Nogowska M, Katny M, Rogowski P, et al.
AAPS PharmSciTech
. 2020 Jun;
21(5):161.
PMID: 32488427
Development of generic extended-release (ER) formulations is challenging. Especially under fed conditions, the risk of failure in bioequivalence trials is high because of long gastric residence times and susceptibility to...